Sarcopenia in Patients With Idiopathic Pulmonary Fibrosis
NCT ID: NCT07178197
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2022-12-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study was designed as a descriptive cross-sectional. The study included patients diagnosed with IPF. Hand dynamometry and bioelectrical impedance analysis (BIA) were used to for diagnose of sarcopenia. Pulmonary function tests, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) measurements were examined. The 6-minute walk distance (6MWD) and 4-meter walking speed were recorded. The St. George Respiratory Questionnaire (SGRQ) was used to assess quality of life. All patients were evaluated for progressive disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis
NCT06668051
Pulmonary and Extrapulmonary Impairments in Patients With Post COVID-19
NCT05381727
Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00258544
Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia
NCT06312774
Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty
NCT06171425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
idiopathic pulmonary fibrosis (IPF)
The prevalence of sarcopenia was investigated in patients with IPF who met the inclusion and exclusion criteria. The relationship between sarcopenia and quality of life and disease progression in patients with IPF was evaluated.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signing the informed consent form
* Having a diagnosis of IPF for at least one month
Exclusion Criteria
* History of cancer within the last 5 years
* History of lung surgery
* History of neuromuscular disease
* Active pulmonary tuberculosis
* Active respiratory tract infection
* Inability to perform pulmonary function tests
* Presence of a pacemaker
* History of systemic steroid use within the past 3 months
* Inability to use a hand dynamometer
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mersin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sibel Naycı
Prof. Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mersin University Faculty of Medicine
Mersin, Mersin, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022/736
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.